/IDYA
IDYA Stock - IDEAYA Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$33.55+0.87%
+$0.29 (+0.87%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.89
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+29.2%upside
Target: $43.35
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IDYA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$33.21 – $33.89
TARGET (TP)$43.33
STOP LOSS$30.87
RISK/REWARD1:3.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.04
52W High$37.08
52W Low$13.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.00M | $23.39M | $50.93M | $27.94M | $19.54M |
| Gross Profit | $3.17M | $19.38M | $48.83M | $26.22M | $18.16M |
| Gross Margin | 45.2% | 82.9% | 95.9% | 93.8% | 92.9% |
| Operating Income | $-326,975,000 | $-134,429,000 | $-62,502,000 | $-50,268,000 | $-35,344,000 |
| Net Income | $-274,477,000 | $-112,961,000 | $-58,655,000 | $-49,762,000 | $-34,495,000 |
| Net Margin | -3921.1% | -483.0% | -115.2% | -178.1% | -176.6% |
| EPS | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.31 |
Company Overview
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
14
88%
Hold / Neutral
2
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
14 Bullish2 Neutral/Bearish
Price Targets
$35
Average Target
↑ 4.5% Upside
Now
$13
Low
$35
Average
$55
High
Based on 19 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| September 18th 2025 | Guggenheim | Initiation | Buy | $50 |
| September 4th 2025 | Barclays | Initiation | Overweight | $40 |
| September 4th 2025 | Citizens JMP | Initiation | Mkt Outperform | $41 |
| July 22nd 2025 | TD Cowen | Initiation | Buy | - |
| July 10th 2025 | Goldman | Resumed | Neutral | $25 |
| June 26th 2025 | Wells Fargo | Initiation | Overweight | $44 |
| November 18th 2024 | Stephens | Initiation | Overweight | $51 |
| November 5th 2024 | Leerink Partners | Downgrade | Market Perform | $27 |
| October 24th 2024 | UBS | Initiation | Buy | $50 |
| October 15th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| July 8th 2024 | Mizuho | Initiation | Outperform | $50 |
| March 8th 2024 | BTIG Research | Initiation | Buy | $55 |
| August 8th 2023 | SVB Securities | Initiation | Outperform | $33 |
| May 24th 2023 | Goldman | Initiation | Buy | $32 |
Earnings History & Surprises
IDYABeat Rate
44%
Last 18 quarters
Avg Surprise
-11.0%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$1.33
Q4 2025
EPS Surprise History
Q1 24
-6.1%
$-0.52vs$-0.49
Q2 24
0.0%
$-0.53vs$-0.53
Q3 24
-23.6%
$-0.68vs$-0.55
Q4 24
+10.4%
$-0.60vs$-0.67
Q1 25
-122.4%
$-1.49vs$-0.67
Q2 25
-9.3%
$-0.82vs$-0.75
Q3 25
-3.5%
$-0.88vs$-0.85
Q4 25
+243.4%
$1.33vs$-0.93
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $-1.03 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.93 | $1.33 | +243.4% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.85 | $-0.88 | -3.5% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.75 | $-0.82 | -9.3% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $-0.67 | $-1.49 | -122.4% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.67 | $-0.60 | +10.4% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.55 | $-0.68 | -23.6% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.53 | $-0.53 | 0.0% | = MET |
Q1 2024 | Feb 20, 2024 | $-0.49 | $-0.52 | -6.1% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.47 | $-0.46 | +2.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.51 | $-0.49 | +3.9% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.57 | $-0.50 | +12.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.65 | $0.04 | +106.2% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.57 | $-0.57 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-0.41 | $-0.36 | +12.2% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-0.31 | $-0.47 | -51.6% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.29 | $-0.31 | -6.9% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.07 | $-0.33 | -371.4% | ✗ MISS |
Latest News
IDYA stock has given up its prior gain. IDEAYA Biosciences shares were trading higher after the company completed targeted full enrollment in its pivotal Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib.
➖ NeutralBenzinga•Dec 11, 2025, 05:51 PM
IDEAYA Biosciences shares are trading higher after the company completed targeted full enrollment in its pivotal Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib.
📈 PositiveBenzinga•Dec 11, 2025, 12:42 PM
Ideaya Biosciences Completed Its Targeted Full Enrollment of 435 Patients In Phase 2/3 OptimUM-02 Trial of Darovasertib Combined With Pfizer's Crizotinib for HLA*A2-Negative Metastatic Uveal Melanoma; Median Progression-free Survival Data is Expected in Q1 2026
📈 PositiveBenzinga•Dec 11, 2025, 11:08 AM•Also:
IDEAYA Biosciences Submits FDA Application for First-in-Class KAT6/7 Dual Inhibitor IDE574, Targets Early 2026 Trials
📈 PositiveBenzinga•Dec 10, 2025, 11:04 AM
On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030
📉 NegativeBenzinga•Dec 5, 2025, 09:26 PM•Also:
Reported Earlier, Biocytogen-Licensed IDEAYA IDE034 Bispecific ADC Wins FDA IND Clearance, Paving Way For Phase 1 Trial And Q1 2026 Patient Enrollment
📈 PositiveBenzinga•Dec 5, 2025, 07:34 AM
IDEAYA Biosciences Secures IND Clearance For IDE034 Bispecific B7H3 PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
📈 PositiveBenzinga•Dec 1, 2025, 11:02 AM
Truist Securities Initiates Coverage On IDEAYA Biosciences with Buy Rating, Announces Price Target of $59
📈 PositiveBenzinga•Nov 24, 2025, 05:57 PM
Mizuho Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $46
📈 PositiveBenzinga•Nov 11, 2025, 02:03 PM
IDEAYA Biosciences Q3 EPS $1.33 Beats $(0.47) Estimate, Sales $207.834M Beat $5.975M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 11:29 AM
Ideaya Biosciences Announces 73,500 Inducement Stock Options Granted To New Employees Under Nasdaq Listing Rule 5635(c)(4)
➖ NeutralBenzinga•Oct 31, 2025, 10:04 AM
JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79
📈 PositiveBenzinga•Oct 23, 2025, 03:53 PM
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30
➖ NeutralBenzinga•Oct 21, 2025, 06:01 PM
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $41
📈 PositiveBenzinga•Oct 21, 2025, 12:09 PM
BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target
📈 PositiveBenzinga•Oct 21, 2025, 10:11 AM
IDEAYA Biosciences Presents Positive Clinical Data From Ongoing Phase 2 OptimUM-09 Trial Of Neoadjuvant Darovasertib In Patients With Primary Uveal Melanoma
📈 PositiveBenzinga•Oct 20, 2025, 10:34 AM
Ideaya Biosciences Reports Median Overall Survival Results From Phase 1/2 Trial (OptimUM-01) Of Darovasertib In Combination With Pfizer's Crizotinib1X For Metastatic Uveal Melanoma
📈 PositiveBenzinga•Oct 20, 2025, 10:12 AM•Also:
Guggenheim Initiates Coverage On IDEAYA Biosciences with Buy Rating, Announces Price Target of $50
📈 PositiveBenzinga•Sep 18, 2025, 01:00 PM
Mizuho Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $44
📈 PositiveBenzinga•Sep 12, 2025, 02:04 PM
IDEAYA Biosciences shares are trading higher. Cantor Fitzgerald maintained its Buy rating on the stock.
📈 PositiveBenzinga•Sep 9, 2025, 05:33 PM
Frequently Asked Questions about IDYA
What is IDYA's current stock price?
IDEAYA Biosciences, Inc. (IDYA) is currently trading at $33.55 per share. The stock has moved +0.87% today.
What is the analyst price target for IDYA?
The average analyst price target for IDYA is $43.33, based on 1 analyst.
What sector is IDEAYA Biosciences, Inc. in?
IDEAYA Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IDYA's market cap?
IDEAYA Biosciences, Inc. has a market capitalization of $2.94 billion, making it a mid-cap company.
Does IDYA pay dividends?
No, IDEAYA Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
FOLD
Amicus Therapeutics, Inc.
$14.18
Mkt Cap: $4.4B
KNSA
Kiniksa Pharmaceuticals, Ltd.
$43.19
Mkt Cap: $3.2B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to IDYA for comparison